Simplifying Global Compliance
FDA Says It Can Approve Follow-On Biologics
Washington Drug Letter
The FDA released a white paper saying it has the ability to approve follow-on biologics without extensive clinical trials, although some trials would be necessary for the follow-ons to replace original products.
To View This Article:
Copyright ©2017. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing